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Objectives. This study was designed to examine the role of
bets-endorphin and met-enkephalin in the pathophysiology of
silent myocardial ischemia, with emphasis on their role in the
physiologic response to stress .
Background. Silent myocardial ischemia is more common in
patients whose perception of pain is reduced . Whether endoge-
nous opiates can contribute to this process remains uncertain
largely because of the
conflicting
findings of previous studies .
Methods. Forty-three patients with coronary artery disease and
ischemia on treadmill stress testing underwent electrical pain tests
and exercise treadmill tests during naloxone and placebo infusion
in a randomized, double-blind crossover study . Thirty-one pa-
tients developed angina during both treadmill tests (group A), and
12 had silent ischemia (group B). Plasma beta-endorphin, met-
enkephalin, epinephrine, norepinephrine and cortisol were mea-
sured before and after exercise in a subgroup of 17 patients .
Results. Naloxone reduced electrical pain tolerance (1 .40
0.10 [mean ± SEM] vs. 1.72 ± 0.19 mA, p = 0 .04) but did
not affect the time to angina in group A (260 ± 20 vs. 248 ± 20 s,
Despite considerable investigation, the mechanisms of silent
ischemia remain controversial . There are two main theories
to explain the lack of symptoms : first, a mass effect that
requires a critical level of myocardial ischemia to stimulate
the nonspecific receptors responsible for angina (1), and
second, abnormalities in pain perception modulated either
centrally, perhaps by endogenous opiates, or peripherally as
a result of a neuropathy (2)
The myocardial afferent nerve supply runs from receptors
in the atria and ventricles by way of the vagus and the
sympathetic supply to the heart (1) . These pathways provide
a potential site for modification of nociception and may be
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p = 0.72) or induce angina in group B patients . Beta-endorphin
and met-enkephalin levels during placebo infusion were not
significantly different in groups A and B at baseline and after
exercise, although beta-endorphin levels were significantly in .
creased during naloxone infusion, confirming effective opiate
receptor blockade. Norepinephrine and cortisol increased with
exercise, but catecholamines and cortisol were similar in both
groups and were unaffected by naloxone .
Conclusions. Beta-endorphin and met-enkephalin were similar
in patients with painful and silent ischemia, and naloxone infusion
did not influence anginal symptoms despite effective opiate recep-
tor blockade and a reduction in somatic pain tolerance . These
AndWgs suggest that endogenous opiates do not play an important
role in modulating symptoms in myocardial ischemia. The in .
crease in beta-endorphin with exercise that coincided with an
increase in plasma cortisol is most likely due to its release from the
anterior plukary gland as part of the physiologic stress response .
(J Ain Cog Cardiol 1994;2 3 :645-51)
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particularly important after acute myocardial infarction (3)
or in diabetic patients with neuropathy (4).
Droste and Roskamm (5) found that patients with silent
ischemia during treadmill testing have a tendency to in-
creased somatic pain thresholds and tolerance, and these
findings were confirmed by Pederson et al . (6) . Several
studies have found differences in beta-endorphin levels in
patients with silent ischemia (7-9), but this has not been a
consistent finding (10), and it is not known whether levels in
peripheral blood reflect variation within the central nervous
system.
This study was designed to reexamine the role of endog-
enous opiates in the pathophysiology of silent myocardial
ischemia, particularly in light of the integral role played by
beta-endorphin and met-enkephalin levels in the physiologic
response to stress .
Methods
Ethical approval. The study was approved by the Newel
ham Health District Ethics Committee, and written informed
consent was given by all patients .
0735-1097194/$7 .00
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Pa . Patients were recruited from those undergoing
exercise treadmill testing for the assessment of angina . All
patients were required to have a normal rest 12-lead electro-
cardiogram (ECG) to minimize ambiguity in interpretation of
ST segment changes during exercise. Any patient who
developed a0.I mV of planar or downslopirg ST segment
depression on exercise treadmill testing was eligible . Pa-
tients underwent coronary by to confirm signifi-
cant coronary artery disease (defined as at least one >70%
diameter stenosis in one or more major coronary arteries) .
Patients with insulin-dependent diabetes were excluded,
but patients with controlled noninsulin-dependent diabetes
were included if there were no microvascular complications .
Patients with any other illnesses or a history of alcohol abuse
were excluded . Normal renal and liver function and normal
hemoglobin levels were confirmed in all cases .
y . Anti . final medication was withdrawn 5
days before the study with the exception of short-acting
nitrates, which were disallowed only on the day of the study .
No medication was taken on the morning of the study . All
studies took place at the same time of day (9:00 AM) with the
patient in the fasting state. Studies were conducted in a
double-blind, randomized crossover fashion between nalox-
one and placebo, and the two experiments were carried out
within I week of each other. An intravenous cannula was
inserted in the left arm at the beginning of the study, and a
6- bolus of naloxone (or 6 ml of normal saline solution)
was given, followed by an infusion at a rate of 0 .1 mg/min
(0.5 m /min) that continued throughout the study . Patients
first underwent an electrical pain test, followed by a 45-min
period of rest and an exercise treadmill test. In a subgroup of
17 consecutive patients, a second cannula was inserted in
the right arm at the beginning of the study, and blood was
taken for assay of plasma levels of beta-endorphin, met-
enkephalin, catecholamines and cortisol, as detailed later .
The study was repeated with the crossover drug within 1
week .
tic pale test
. Somatic pain was assessed by using
electrical pain stimulation (11) . A constant current stimula-
tor was used to compensate for varying resistance with
sweating, ar.d a square wave stimulus at a frequency of
50 Hz with an impulse duration of 5 ms was applied
.
Electrodes were attached to the right forefinger, 20 mm
apart, and an increasing current was applied
. All patients
were given standard instructions . The patient indicated the
threshold of pain by pressing a buzzer and indicated the limit
of tolerance by pressing the buzzer a second time . Studies
were conducted in an environment free from disturbance,
and the patients wore earplugs to eliminate background
noise .
. This test was performed accord-
ing to the Bruce protocol, using a Marquette Case 12
treadmill. A 12-channel ECG was monitored continuously,
and two ECGs were recorded at baseline and every 30 s
throughout the study . Heart rate was monitored throughout
the test, and blood pressure was recorded at baseline, at the
end of each stage and at peak exercise . To obtain objective
measurement of the onset of pain, no communication was
made with the patient during the test, and the patient
indicated the onset of angina by pressing a buzzer. Exercise
was stopped when the patient pressed the buzzer for the
second time or if any of the following occurred : a decrease in
systolic blood pressure >10 mm Hg, significant ventricular
arrhythmias or >0 .5 mV ST segment depression. In this
study, it was not necessary to stop the treadmill test for any
of these reasons . Thirty-one patients developed angina dur-
ing both treadmill tests and constituted group A, whereas 12
did not and constituted group B .
Blood m es, Uncuffed blood samples were taken from
the intravenous cannula for assay of beta-endorphin, met-
enkephalin, epinephrine, norepinephrine and cortisol levels .
The patients rested after pain testing, and samples were
drawn after 30 min of rest and 15 min later, immediately
before exercise treadmill testing . The mean value of these
two results was considered the baseline value . Further
samples were taken at peak exercise and at 15 and 60 min
after peak exercise, during a further period of rest . After
centrifugation, plasma was frozen in liquid nitrogen within
15 min and stored at -20'C until assayed .
Assay of beta-endorphin and met-enkephalin levels .
Plasma beta-endorphin (12) and met-enkephalin (13,14) were
measured by radioimmunoassay . The lowest detection limits
of the assay were 10 and I pg/ml, respectively . The intra-
assay and interassay coefficients of variation were 5 .9% and
8.9% for beta-endorphin and 7 .9% and 9.8% for met-
enkephalin, respectively.
y of catedida iand curt° l levels . Plasma epi-
nephrine and norepinephrine were measured by liquid chro-
matography and electrochemical detection (15) . The lowest
detection limit for both assays was 0.05 nmol/liter. The
intraassay and interassay coefficients of variation were 5 .1%
and 7.5% for epinephriae and 3 .7% and 6.6% for norepineph-
rine, respectively . Serum cortisol was measured by radioim-
munoassay (16) . The lowest detection limit of the assay was
50 nmollliter. The intraassay and interassay coefficients of
variation were 6 .9% and 8 .0%, respectively .
Statistical ysis . All averaged results are expressed as
mean value ± SEM. The significance of differences between
groups A and B and between naloxone and placebo was
obtained by repeated measures analysis of variance . The
distribution of diabetic patients, gender and presence of
multivessel coronary artery disease was measured by using
the chi-square test with the Yates correction where appro-
priate. Where an important negative result was obtained, the
power of the study to detect a significant difference at the 5%
level was assessed .
Results
Patients . Of the 43 patients included in the study, 31
experienced angina during both the placebo and the nalox-
one treadmill stress tests (group A) . The remaining 12
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patients (group B) did not experience angina during either
test (9 patients) or during only one test (3 patients) . The
groups were similar with regard to age (60
'
2 vs. 65 ± 2
years, p = 0.17), gender distribution (25 men vs . 9 men,
p = 1 .0) and prevalence of diabetes (8 vs . 5, p = 0 .31) .
Patients in group A tended to have more extensive coronary
artery disease than those patients in group B, as measured
by the Gensini score (50 .5 ± 6.2 vs . 32 .6 ± 10.7), but this
difference was not significant (p = 0.15) .
Halter ST segment monitoring . Ischernic ST segment
depression was recorded in 35 patients during 48-h monitor-
ing (28 in group A, and 7 in group B). Group B had a
significantly higher proportion of silent ischemia during the
p= ®13
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monitoring period than group A (0 .65 ± 0 .06 vs . 0 .98 ± 0 .01,
p = 0.02) .
Somatic pain threshold (Fig . 1). Naloxone infusion
vs. 112 ± 0.19 mA, p = 0.04) compared with placebo,
suggesting effective opiate receptor blockade in the 43
patients studied . There were no significant differences be-
tween groups A and B either in the placebo measurements or
in the responses to naloxone (80% power to detect a 50%
difference) .
Treadmill stress testing . Hemodynamic response (Table 1) .
Exertional increases in heart rate and blood pressure provoked
Table 1 . Hemodynarnic, lschemic and Symptomatic Responses to Exercise Treadmill Testing: Naloxone Versus Placebo in Groups A
and B .*
Naloxone
*There are no significant differences between naloxone and placebo in any variables . Data presented are mean value ± SEM . Group A = patients with, and
Group B = patients without, angina on treadmill exercise testing .
Group A
(n = 31)
Group B
(n = 12)
p
Value
82 ± 3 77 ± 4 0 .26
117 ± 3 123 ± 6 0 .48
131 ± 3 142 ± 6 0 .24
139 ± 5 145 ± 7 0 .47
150 ± 4 156 ± 6 0 .37
164 ± 5 172 ± 7 0 .30
HA± 15 11 .1±0 .8 0 .64
17 .5 ± 0 .7 19.3±1 .4 00 .21
19 .7 ± 0 .8 21.7±1.6 00 .32
180 ± 18 276 ± 32 0 .02
307 ± 20 464 ± 47 0 .004
0.83 ± 0 .08 0 .71 ± 0.37 0 .73
Group A
(n = 31)
Group B
(n = 12)
p
Value
81±2 77±5 0.51
116±2 120±6 0 .50
132 ± 3 139 ± 7 0 .38
133 ± 5 147 ± 6 0 .13
146 ± 4 157 ± 6 0 .13
155 ± 4 170 ± 7 0 .06
10.9±0.5 11 .3 ± 0 .9 0.53
17.0±0.6 18 .91- 1 .4 0.16
18.8±8.5 22.1±1 .5 00
200 ± 16 270 ± 36
0.08
325 ± 21 464 ± 17 0.01
0.81 z 0 .10 0.71 ± 0 .33 0.75
caused reductions in electrical pain threshold (1 .09 0.11
vs . 1 .33 ± 0.18 mA, p = 0 .13) and pain tolerance (1 .40 0.10
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lure 2. Plasma beta-endorphin and met-enkephalin levels at rest,
peals exercise and recovery (15 and 60 min) . The effects of naloxone
versus placebo for all patients (n = 17) are shown and also for
subgroups with symptoms (group A, n =11) and without symptoms
(group B, n - 6). 0 = beta-endorphin during placebo infusion ; N -
beta-endorphin during naxolone infusion ; A - met-enkephalin dur-
ing placebo infusion; V - met-enkephalin during naloxone infusion .
I - liter .
ischemic ST segment depression in every patient. During
placebo infusion, group A developed ischernia at an earlier
stage than did group B (180 ± 18 vs . 276 t 32 s, p = 0 .02) and
stopped exercising earlier (307 ± 20 vs. 464 t 47 s, p = 0.004).
These hemodynamic and ischemic responses were unafected
by naloxone infusion and for both groups, rate-pressure prod-
ucts at do onset of ischemia and at peak exercise were similar
to the values obtained during placebo infusion .
Despite effective opiate receptor blockade, naloxone did
not affect symptomatic responses to-exertional ischemia.
Thus, the time to onset of angina in group A did not shorten
(260 ± 20 vs . 248 ± 20 s, p = 0.72), and none of the group B
patients with silent ischemia during placebo infusion expe-
21 All patients (n=17)
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W
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rienced angina during naloxone infusion . Exercise duration
was also unaffected by naloxone (364 ± 22 vs . 351 ± 22 s,
p = 36) .
Neurohumoral responses . 1) Beta-endorphin (Fig . 2) .
Exercise produced a small increase in plasma levels of
beta-endorphin that was statistically significant (p = 0.04) .
During placebo infusion, plasma levels were higher in group
A than group B both at rest (28.7 ± 2.8 vs. 18 .9 ± 2.2 ng/1)
and at peak exercise (30.9 ± 3 .0 vs . 20.2 ± 4.5 ng/l, p =
0.03). Naloxone infusion increased plasma levels in both
groups (p = 0.02), indicating effective opiate receptor block-
ade. There were no differences between the groups in the
magnitude fff their response to naloxone (800/c power to
detect a 5010 difference). 2) Met-enkephalin (Fig . 2) . Plasma
levels of met-enkephalin were similar in groups A and B and
were unaffected by exercise or naloxone infusion (80%
power to detect a 10OVo difference) . 3) Catecholamines (Fig .
3). Plasma levels of norepinephrine increased significantly
(p < 0 .001) during exercise in groups A and B . Responses
were quantitatively similar in both groups (p = 0 .08) and
were unaffected by naloxone . Plasma epinephrine showed
Figure 3. Plasma epinephrine and norepineph-
rine measured in 17 patients at rest, peak exercise
and recovery (15 and 60 min) . The effects of
naloxone versus placebo are shown . A = norepi-
nephrine during placebo infusion ; 0 = epineph-
rine during placebo infusion ; V = norepinepnrine
during naloxone infusion ; 0 = epinephrine dur-
ing naloxone infusion . I = liter .
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Figure 4. Plasma cortisol measured in 17 patients at
rest, peak exercise and recovery (15 and 60 min) .
The effects of naloxone (V) versus placebo (A) are
shown . I = liter .
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no change during exercise and was unaffected by naloxone
(8017b power to detect a 100% difference) . 4) Cortisol (Fig . 4) .
Plasma cortisol levels were markedly increased during nal-
oxone infusion (p = 0.001) and showed a small increase after
exercise that did not reach significance (p = 0 .09 [NSII) .
Responses were similar in groups A and B (p = 0.88) .
Discussion
In this study two groups of patients with angiographically
proved coronary artery disease were compared to investi-
gate the role of endogenous opiates (beta-endorphin and
met-enkephalin) in modulating the perception of myocardial
ischemia . In one group, cxertionall ischemia during treadmill
testing consistently provoked angina, whereas in the other
group, ischernia was commonly silent . The predisposition of
the latter group to silent ischemia was confirmed by Holter
ST segment monitoring but, despite this, plasma levels of
beta-endorphin in this group were lower than in the symp-
tomatic group and showed no tendency to have a greater
increase more acutely during exercise . The data therefore
suggest that endogenous opiates do not contribute signifi-
cantly to the pathogenesis of silent ischemia .
Relation between silent ischemia and endogenous opiates .
The potential role of endogenous opiates in modulating
symptomatic responses to myocardial ischerniaa has been
examined in previous studies (9,10,17-19), but the findings
have been conflicting. Thus, Heller et al . (10) found no
difference in beta-endorphin levels either before, during or
after exercise when comparing patients with silent and
symptomatic ischemia on treadmill testing . Like us, these
investigators concluded that endogenous opiates were un-
likely to play an important role . However, other investiga-
tors have reported higher rest levels of beta-endorphin (17)
or a larger increase during exercise (9) in patients with silent
ischemia on treadmill testing, leading Droste et al . (9) to
conclude that these substances may indeed play a major role
in modulating symptomatic responses to myocardial isch-
emia. In contrast to the patients studied by Falcone et al .
MARCHANT ET AL.
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(17) and Droste et al . (9), all patients in the present study had
a history of angina and none had a previous myocardial
infarction, so that direct comparison between studies should
be made cautiously .
Naloxone as an investigative tool. One possible explana-
tion for these conflicting findings is that plasma concentra-
tions of endogenous opiates may not accurately reflect their
concentrations within the central nervous system and may
not, therefore, provide an accurate guide to their pain-
modulating activity . To obtain additional information about
the central effects of endogenonss opiates on the perception
of exertional myocardial iscnemia, we measured the effects
of naloxone infusion on the hemodynamic, ischemic and
symptomatic responses to treadmill exercise . Naloxone is a
specific opiate receptor antagonist with variable dose-related
effects on different opiate receptors : Mu-receptors are sen-
sitive to low doses of naloxone, but adequate blockade of the
kappa- and delta-receptors requires substantially higher
doses (20) . For this reason we used a 6-mg bolus dose of
naloxone followed by an infusion of the drug at 0 .1 mg/min to
ensure that full opiate receptor blockade was maintained
throughout the exercise test and recovery period . The high
dose of naloxone did not influence hemodynamic or ischemic
responses to exercise, as reflected by rate-pressure product
or time to onset of ischemia, nor did it affect the stress
response, as judged by plasma catecholamine levels. How-
ever, the significant increase in plasma beta-endorphin sug-
gested that the naloxone dosage was effective in blocking
central opiate receptors, a suggestion confirmed by the
measured levels of somatic pain tolerance, which decreased
significantly .
Despite effective blockade of central opiate receptors
during naloxone infusion, the symptomatic responses to
treadmill exercise in both groups lend further support to our
major conclusion that endogenous opiates do not contribute
significantly to the pathophysiology of silent ischemia
. Thus,
naloxone infusion did not cause angina to occur earlier in
group A and failed to induce angina in any of those group B
patients who had a silent stress test during placebo infusion
.
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These findings with naloxone are in broad agreement with
those of Ellestad and Kuan (18), who failed to induce angina
in 10 asymptomatic patients, and also with Weidinger et al .
(21), who did not observe any difference in the onset of
symptoms in 10 patients. However, both of these studies
used small doses of naloxone (2 mg and 1 .2 mg by intrave-
nous bolus, respectively), and it is possible that effective
opiate receptor blockade was not achieved. Only Droste et
al. (9) used the 6-mg bolus dose of naloxone used in our
studies (albeit without the continuing naloxone infusion we
used), nevertheless, their findings conflict with our own in a
way that cannot be readily explained . Thus, even though
naloxone caused no reduction in electrical pain threshold (a
finding at variance with that of other investigators (221), in
their study angina was induced in two of nine asymptomatic
patients and occurred earlier in seven of eight symptomatic
patients .
Role of e noun opiates in the physiologic response so
. Although our findings are different from those of
Droste et al. (9) in not supporting a role for endogenous
opiates in the pathophysiology of silent ischemia, the find-
ings of both studies are entirely consistent with the known
involvement of endogenous opiates in the normal stress
response . Met-enkephalin is secreted from the adrenal me-
dulla, where it is contained in the same vesicles as epineph-
rine and norepinephrine (23) . Thus, it increases dramatically
during an insulin stress test (24,25) but not in response to the
sympathetic stimulation that occurs during exercise (26) .
Beta-endorphin, in contrast, is secreted by the anterior
pituitary gland (together with adrenocorticotrophin hor-
mone) in response to stimulation by corticotrophin-releasing
hormone (27) . This secretion tends to occur shortly after
stress, accounting for the peak in plasma beta-endorphin
15 min after exercise (28) . Negative feedback by endogenous
opiates on the release of adrenocorticotrophin hormone was
inhibited by naloxone, leading to markedly increased levels
of cortisol, which demonstrated a similar pattern to beta-
endorphin .
of study. In studies of this type there is
inevitably a subjective element to the interpretation of
ischemic and symptomatic end points, which may account in
part for the conflicting findings of different investigators and
for the continuing uncertainties about the mechanisms of
silent ischemia. For this reason, particular care was taken to
maximize the quality of the data by paying careful attention
to methodology. Thus, only untreated patients with angio-
graphically proved coronary artery disease and a normal rest
ECG were included to avoid any ambiguity in the interpre-
tation of ischemic ST segment changes . During treadmill
stress testing, the patients were fitted with wax earplugs, and
their only communication with the investigator was to indi-
cate the onset of angina and limit of exercise tolerance by
pressing a buzzer
. By these means, bias on the part of
patient and investigator in detecting and recording (respec-
tively) the onset of angina and exercise capacity was effec-
tively excluded by minimizing auditory and verbal distrac-
JACC Vol . 23, No . 3
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tion . Hotter monitoring was continued for a full 48 h to allow
for random variation in the prevalence of ischemia, and
before each study recordings were made in each of five
positions to rule out any posture-induced ST segment or T
wave changes . Finally, special attention was given to tech-
niques used in blood sampling, storage and analysis to
ensure that the laboratory data were accurate .
Conclusions. The patients in this study with silent exer-
tional ischemia did not have increased plasma levels of
endogenous opiates compared with symptomatic control
subjects. Moreover, despite effective central blockade of
opiate receptors with naloxone, exel.tional angina was not
induced in these patients, nor was the time to angina
shortened in the symptomatic control subjects . The data
therefore provide no support for the hypothesis that varia-
tions in the central modulation of pain by endogenous
opiates account for variations in the perception of angina
seen in patients with silent and symptomatic exertional
ischemia . The increase in beta-endorphin levels with exer-
cise that coincided with an increase in plasma cortisol is
most likely due to its release from the anterior pituitary gland
as part of the physiologic response to stress .
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